SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950142-24-001002
Filing Date
2024-04-08
Accepted
2024-04-08 20:05:48
Documents
1
Period of Report
2024-04-05

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT eh240467037_4-ngm3.html 4  
1 OWNERSHIP DOCUMENT eh240467037_4-ngm3.xml 4 35644
  Complete submission text file 0000950142-24-001002.txt   37365
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Issuer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 LETTERMAN DRIVE, BUILDING D SUITE DM-900 SAN FRANCISCO CA 94129
Business Address 1 LETTERMAN DRIVE, BUILDING D SUITE DM-900 SAN FRANCISCO CA 94129 415-865-2050
TCG Opportunity III GP, LLC (Reporting) CIK: 0001932445 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38853 | Film No.: 24830911